Design and discovery of neuropeptide Y-1 receptor antagonists

被引:11
|
作者
Wright, J
机构
[1] Department of Chemistry, Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor
关键词
D O I
10.1016/S1359-6446(96)10049-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neuropeptide Y (NPY) has been the focus of much attention since its discovery as the most abundant peptide in mammalian brain. It has been implicated in many roles in both the periphery and the CNS. The first cloned receptor subtype, Y-1, has been identified as an important mediator for many of these effects. Potent, selective Y-1 receptor antagonists have been developed and have certainly helped clarify the peripheral roles of NPY and the receptors involved. However, there is still a need for Y-1 antagonists that can be administered peripherally, even orally, and penetrate the CNS. Such compounds would help define the roles of NPY and Y-1 receptors in the CNS, an area rich in potential for novel drug therapy.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 50 条
  • [1] Y-1 AND Y-2 RECEPTOR-SELECTIVE NEUROPEPTIDE-Y ANALOGS - EVIDENCE FOR A Y-1 RECEPTOR SUBCLASS
    KIRBY, DA
    KOERBER, SC
    MAY, JM
    HAGAMAN, C
    CULLEN, MJ
    PELLEYMOUNTER, MA
    RIVIER, JE
    JOURNAL OF MEDICINAL CHEMISTRY, 1995, 38 (22) : 4579 - 4586
  • [2] Neuropeptide Y Y-1 receptor mechanisms in sympathetic vascular control
    Malmstrom, RE
    ACTA PHYSIOLOGICA SCANDINAVICA, 1997, 160 : 4 - 55
  • [3] Rapid parallel synthesis applied to the optimization of a series of potent nonpeptide neuropeptide Y-1 receptor antagonists
    Siegel, MG
    Chaney, MO
    Bruns, RF
    Clay, MP
    Schober, DA
    Van Abbema, AM
    Johnson, DW
    Cantrell, BE
    Hahn, PJ
    Hunden, DC
    Gehlert, DR
    Zarrinmayeh, H
    Ornstein, PL
    Zimmerman, DM
    Koppel, GA
    TETRAHEDRON, 1999, 55 (39) : 11619 - 11639
  • [4] Neuropeptide Y potentiates noradrenaline-induced contraction through the neuropeptide Y Y-1 receptor
    Bergdahl, A
    Nilsson, T
    Cantera, L
    Nilsson, L
    Sun, XY
    Hedner, T
    Erlinge, D
    Valdemarson, S
    Edvinsson, L
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 316 (01) : 59 - 64
  • [5] Neuropeptide Y receptor gene regulation in mouse adrenocortical Y-1 cells
    Weng, GZ
    Feinstein, D
    Reis, D
    Wahlestedt, C
    REGULATORY PEPTIDES, 1996, 63 (01) : 53 - 56
  • [6] Structure-activity relationships of a series of 1-substituted-4-methylbenzimidazole neuropeptide Y-1 receptor antagonists
    Zimmerman, DM
    Cantrell, BE
    Smith, ECR
    Nixon, JA
    Bruns, RF
    Gitter, B
    Hipskind, PA
    Ornstein, PL
    Zarrinmayeh, H
    Britton, TC
    Schober, DA
    Gehlert, DR
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (05) : 473 - 476
  • [7] Neuropeptide Y receptor antagonists
    Ling, AL
    EXPERT OPINION ON THERAPEUTIC PATENTS, 1999, 9 (04) : 375 - 384
  • [8] Receptor subtypes Y-1 and Y-5 are involved in the renal effects of neuropeptide Y
    Bischoff, A
    Avramidis, P
    Erdbrugger, W
    Munter, K
    Michel, MC
    BRITISH JOURNAL OF PHARMACOLOGY, 1997, 120 (07) : 1335 - 1343
  • [9] Monitoring of antisense effects of oligonucleotides targeted to the neuropeptide Y Y-1 receptor gene
    Hanze, J
    Worgall, S
    Rascher, W
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 330 (01) : 87 - 92
  • [10] Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor antagonists
    Griffith, David A.
    Hargrove, Diane M.
    Maurer, Tristan S.
    Blum, Charles A.
    De Lombaert, Stephane
    Inthavongsay, John K.
    Klade, Lee E.
    Mack, Christine M.
    Rose, Colin R.
    Sanders, Martin J.
    Carpino, Philip A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (09) : 2641 - 2645